Boston Scientific exceeds most expectations in Q2

However, the US-based medtech firm, and Ambu competitor on the endoscopy market, missed one analyst projection by a smidge.

US-based Boston Scientific, a competitor of Danish medtech firm Ambu on the endoscope market, has handed in a second quarterly report with better-than-expected bottom and top lines, when examining the firm’s financial figures next to the analysts consensus estimate.

In the three months ending June, net sales came to USD 3.24bn, or organic growth of 5.4%. Projections had put the firm’s sales at USD 3.22bn.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs